通过milciclib介导的CDK2抑制来提高结直肠癌中放射治疗的敏感性
Junjie Ma1,2, Shanshan Wu1,2, Xinxin Yang1,2
1School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Frontiers in pharmacology
|April 9, 2025
概括
在结直肠癌 (CRC) 细胞中,Milciclib显示出抗瘤作用,并通过破坏细胞循环和DNA修复来增强放射治疗的有效性. 这表明Milcicliblib.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 辐射疗法 辐射疗法
背景情况:
- 大肠直肠癌 (CRC) 是全球领先的癌症.
- 放射治疗耐药性是治疗局部晚期直肠癌的一个主要挑战.
- 需要新的治疗目标来改善CRC治疗结果.
研究的目的:
- 评估Milciclib在结直肠癌 (CRC) 细胞中的抗瘤作用.
- 为了确定Milciclib是否可以增强CRC细胞的放射敏感性.
- 评估Milciclib在耐辐射CRC模型中的有效性.
主要方法:
- 细胞活力,细胞周期和细胞亡测定在HCT116和RKO CRC细胞系上进行.
- 单独使用Milciclib和与辐射结合治疗CRC细胞.
- 评估了Milciclib在抗辐射CRC细胞中的疗效.
主要成果:
- 米尔西克利布表现出剂量依赖的细胞毒性,IC50值为0.275μM (HCT-116) 和0.403μM (RKO).
- 米尔西克利布诱导了G2/M细胞循环停止,并促进了细胞亡.
- 使用Milciclib和辐射的联合治疗通过破坏DNA修复 (Rad51抑制) 增强了放射性敏感性,并且在耐药细胞中显示了敏感剂增强比率 (SER) >1.
结论:
- 在CRC细胞中,milciclib作为单一疗法表现出显著的抗瘤活性.
- 通过破坏细胞循环检查点和DNA修复,Milciclib提高了放射治疗的有效性.
- 米尔西克利布显示出作为治疗剂的潜力,可以克服CRC中的放射疗法耐药性.
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


